Irinotecan for Advanced and Metastatic Breast Cancer

Summary

This trial aims to evaluate the safety and efficacy of third-line or later irinotecan treatment for locally recurrent or metastatic breast cancer among Chinese patients who have received at least two regimens containing anthracyclines and taxanes.

Timeline

Start

2017-04-01

Primary completion

2020-01

Completion

2021-12

Drugs

Indications